ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

• Published in: Modern pathology Vol. 25; no. 3; pp. 471 - 479
• Main Authors: Hoogland, A Marije, Jenster, Guido, van Weerden, Wytske M, Trapman, Jan, van der Kwast, Theo, Roobol, Monique J, Schröder, Fritz H, Wildhagen, Mark F, van Leenders, Geert JLH
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.03.2012; Elsevier Limited
• Subjects: Adenocarcinoma; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - surgery; Aged; Androgen receptors; Androgens; Antigens; Biomarkers, Tumor - metabolism; DNA microarrays; ERG gene; ERG protein; ETS protein; Gene fusion; gene rearrangement; Genes; genomics; Humans; Immunohistochemistry; Laboratory Medicine; Male; Medical screening; Medicine; Medicine & Public Health; Middle Aged; Multivariate analysis; Neoplasm Recurrence, Local - diagnosis; original-article; Pathology; Patients; Polymerase chain reaction; Predictive Value of Tests; Prognosis; Prostate cancer; prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - mortality; Prostatic Neoplasms - surgery; Protein expression; Proteinase; Proteins; Receptors, Androgen - metabolism; Serine; Survival; Survival Rate; Trans-Activators - metabolism; Transcription factors; Transcriptional Regulator ERG; Tumors; Ultrasonic imaging; Xenografts; Netherlands; recurrence; progression; prostate cancer; ERG; immunohistochemistry

In prostate cancer genomic rearrangements involving genes encoding ETS transcription factors are commonly present, with androgen-regulated transmembrane protease , serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogen homologue (ERG) gene fusion occurring in 40–70%. Studies on the predictive v...